The E-Pharmacy is an off-shoot of modern technology. The benefits of internet pharmacies propagated are convenience; allow the door delivery of drugs at low cost, but the picture presented is misleading and hiding the facts, says All India Organisation of Chemists and Druggists (AIOCD) as a objection towards ePharmacy working in India.
The Competition Commission of India (‘Commission’) has found Madhya Pradesh Chemists and Druggist Association (‘MPCDA’), Indore Chemists Association (‘ICA’), Himalaya Drug Company (‘HDC’) and Intas Pharmaceuticals Limited (‘IPL’) along with some of their office bearers/officials to be in contravention of the provisions of the Competition Act, 2002 (‘Act’).
Pharmacy Council of India has reportedly directed universities to use the prefix 'Doctor (Dr)' while awarding degrees to Pharm.D graduates. Indian Medical Association strongly opposes any move from those who are trained in other streams of Health sector to venture into medical practice.
Connecticut Attorney General William Tong is leading a 44-state coalition in an antitrust lawsuit against 20 makers of generic drugs and 15 individuals, claiming the companies conspired to fix prices for 114 medications.
Indian Pharmacists Association (IPA) strictly opposes use of the post name Dispensing Attendant instead of Pharmacist for recent recruitment advertisement by AIIMS Rishikesh. As per IPA, the advertisement No. 2019/153 by AIIMS Rishikesh is violating Pharmacy Act and Drugs and Cosmetic rules.
Limited access to essential medicines for treating chronic diseases is a major challenge in low and middle-income countries. Although India is the largest manufacturer of generic medicines, there is a paucity of information on availability, price and affordability of essential anti-cancer medicines used for treating childhood cancers.
The National Pharmaceutical Pricing Authority (NPPA), under Ministry of Chemicals & Fertilizers, today put out list of 390 anti-cancer non-scheduled medicines with MRP reduction up to 87%. The revised prices would come into effect from 8th March, 2019.
EMA is advising healthcare professionals and patients not to exceed the recommended dose of Xeljanz (tofacitinib) when treating rheumatoid arthritis. The advice follows early results from an ongoing study (study A3921133) in patients with rheumatoid arthritis which showed an increased risk of blood clots in the lungs and death when the normal dose of 5 mg twice daily was doubled.
A section of the media has reported that a seven year old boy from Malappuram District of Kerala is suffering from a West Nile Virus (WNV), a mosquito-borne disease, mostly reported in the continental United States. Union Minister of Health and Family Welfare is closely monitoring the situation and has spoken to the State Health Minister of Kerala in this regard. He has directed for all support to be extended to Kerala in its prevention and management.
Pharmacy council of India (PCI) announced for digital learning platform for pharmacists and it will be helpful for pharmacists to gain knowledge as per PCI members. As per PCI, continuous learning of pharmacists will be supported through their digital platform.